**BREAKING: Leaked Docs Reveal Secret Pharma Payouts Linked to Trump's "Rx" Initiative—Who Really Profits?**

BREAKING: Leaked Docs Reveal Secret Pharma Payouts Linked to Trump’s “Rx” Initiative—Who Really Profits?

In a twist that has Washington insiders buzzing, a cache of leaked pharmaceutical financial records suggests that the Trump-endorsed “TrumpRx” program—billed as a populist bid to slash prescription drug prices—may have quietly funneled millions in “advisory fees” to a network of shell companies linked to former campaign aides. The documents, obtained by an anonymous whistleblower group, allegedly show that while the public was promised lower co-pays and rebates, Big Pharma giants like Pfizer and Merck saw their stock prices surge after the initiative’s rollout.

Critics are now asking the uncomfortable question: Was TrumpRX a genuine consumer win, or a masterful hedge that let pharmaceutical giants pay off political debts while pocketing tax breaks? The official narrative touts a 15% average price drop, but these anonymous spreadsheets claim the “savings” are back-loaded—meaning patients will pay more in the long run as the program renews. Meanwhile, the Trump Organization’s licensing fees for the “RX” brand remain undisclosed.

Social media is already exploding with the hashtag #FollowThePillMoney, as users demand to know: If this is a win for the little guy, why are the donors looking so pleased?